A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.

开始日期2025-01-01

申办/合作机构

ITM Solucin GmbH

NCT05918302

/ Recruiting临床3期IIT

Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

开始日期2023-10-27

申办/合作机构

Itm Isotope Technologies Munich SE

100 项与镥[177Lu]依多曲肽相关的临床结果

登录后查看更多信息

100 项与镥[177Lu]依多曲肽相关的转化医学

登录后查看更多信息

100 项与镥[177Lu]依多曲肽相关的专利（医药）

登录后查看更多信息

项与镥[177Lu]依多曲肽相关的文献（医药）

2024-06-01·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors

Article

作者: Jentzen, Walter ; van Echteld, Cees J A ; Meckel, Marian ; Fendler, Wolfgang P ; Himmen, Stephan ; Coelho, Marta ; Fragoso Costa, Pedro ; Sraieb, Miriam ; Herrmann, Ken ; Moraitis, Alexandros ; Kersting, David

Para-aminohippurate, also known as p-aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce ¹⁷⁷Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. Methods: Twelve patients with metastatic or unresectable gastroenteropancreatic neuroendocrine tumors received ¹⁷⁷Lu-DOTATOC in 33 treatment cycles. Either 8 g of PAH or a mixture of 25 g of arginine and 25 g of lysine were coinfused. Safety was assessed by monitoring laboratory data, including hematologic and renal data, as well as electrolytes obtained before and 24 h after treatment. For radiation dosimetry, whole-body scans were performed at 1, 24, and 48 h and a SPECT/CT scan was performed at 48 h, along with blood sampling at 5 min and 0.5, 2, 4, 24, and 48 h after administration. Absorbed dose estimations for the kidneys and bone marrow were performed according to the MIRD concept. Results: In 15 treatment cycles, PAH was coinfused. No changes in mean creatinine level, glomerular filtration rate, and serum electrolytes were observed before or 24 h after treatment when using PAH protection (P ≥ 0.20), whereas serum chloride and serum phosphate increased significantly under AA (both P < 0.01). Kidney-absorbed dose coefficients were 0.60 ± 0.14 Gy/GBq with PAH and 0.53 ± 0.16 Gy/GBq with AA. Based on extrapolated cumulative kidney-absorbed doses for 4 cycles, 1 patient with PAH protection and 1 patient with AA protection in our patient group would exceed the 23-Gy conservative threshold. The bone marrow-absorbed dose coefficient was 0.012 ± 0.004 Gy/GBq with PAH and 0.012 ± 0.003 Gy/GBq with AA. Conclusion: PAH is a promising alternative to AA for renal protection during peptide receptor radiotherapy. Further research is required to systematically investigate the safety profile and radiation dosimetry at varying PAH plasma concentrations.

2024-01-01·Theranostics

Long-term Nephrotoxicity after PRRT: Myth or Reality

Article

作者: Yu, Fei ; Zhang, Jingjing ; Baum, Richard P ; Schuchardt, Christiane ; Fan, Xin ; Chen, Xiaoyuan ; Jakobsson, Vivianne

Rationale: The kidneys are commonly considered as the potential dose-limiting organ for peptide receptor radionuclide therapy (PRRT), making the risk of nephrotoxicity a primary concern. This retrospective analysis with prospective documentation and long-term follow-up aims to assess the risk of nephrotoxicity after PRRT in a large cohort of patients with neuroendocrine neoplasms (NENs) treated at our institution over the past 18 years. Methods: A total of 1361 NEN patients treated with 1-10 cycles of ¹⁷⁷Lu-DOTA-TOC/-NOC/-TATE, ⁹⁰Y-DOTA-TOC/-NOC/-TATE, DUO-PRRT (sequential administration of ⁹⁰Y- and ¹⁷⁷Lu-), or TANDEM-PRRT (combination of ⁹⁰Y- and ¹⁷⁷Lu- on the same day concomitantly) were included in this analysis. All parameters were prospectively documented in a structured database comprising over 250 items per patient and retrospectively analyzed. Kidney function, including serum creatinine, blood urea nitrogen, cGFR, and electrolytes, was evaluated before each PRRT cycle and during follow-up. Restaging was regularly performed at 6-month intervals until death. Treatment-related adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0). Results: Between 2000 and 2018, a total of 5409 cycles of PRRT were administered to 1361 NEN patients. Follow-up after complete treatment was available for 1281 patients receiving 4709 cycles of PRRT, with a median follow-up time of 69.2 months (interquartile range, 32.8-110.5 months) and a maximum follow-up time of 175 months. Baseline creatinine levels were normal in 1039/1281 (81.1%) subjects, while grade 1 (G1) renal insufficiency was present in 221/1281 (17.3%) prior to PRRT. G2 was present in 19/1281 (1.5%), and G3 in 2/1281 (0.2%). After treatment, the proportion of G3/G4 grade patients only increased from 0.2% to 0.7%. Mean creatinine levels increased from a baseline of 0.90 ± 0.30 to 1.01 ± 0.57 mg/L (80.0 ± 26.7 to 89.4 ± 50.8 μmol/L) after treatment. In our main analysis cohort of 1244 patients (4576 cycles), 200 patients experienced an increase in CTCAE creatinine grade. Age, number of treatment cycles, type of radionuclides, and length of follow-up time were the main factors affecting CTCAE creatinine grading after treatment. When comparing the subgroups treated with different radionuclides, the risk of nephrotoxicity after ⁹⁰Y treatment alone and the ⁹⁰Y/¹⁷⁷Lu combination group was higher than after ¹⁷⁷Lu treatment alone. In the ⁹⁰Y treatment subgroup, the two significant risk factors for an increased CTCAE creatinine grade were identified to be age (≥60) and a long follow-up time. Conclusions: This retrospective analysis with prospective documentation in a large cohort of 1281 NEN patients receiving 4709 cycles of PRRT co-administered with renal protection, treated through the individualized approach at a single institution over 18 years, did not reveal any evidence of long-term PRRT-related renal toxicity. The results of our study suggest that with the use of proper renal protection, nephrotoxicity due to PRRT is more likely a myth than a reality.

2023-07-01·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of ¹⁶¹Tb into the Clinic.

Article

作者: Landolt, Stefan ; van der Meulen, Nicholas P ; Grundler, Pascal V ; Talip, Zeynep ; Sepini, Lebogang ; Köster, Ulli ; Schibli, Roger ; Favaretto, Chiara ; Geistlich, Susanne ; Müller, Cristina

¹⁶¹Tb is an interesting radionuclide for application in the treatment of neuroendocrine neoplasms' small metastases and single cancer cells because of its conversion and Auger-electron emission. Tb has coordination chemistry similar to that of Lu; therefore, like ¹⁷⁷Lu, it can stably radiolabel DOTATOC, one of the leading peptides used for the treatment of neuroendocrine neoplasms. However, ¹⁶¹Tb is a recently developed radionuclide that has not yet been specified for clinical use. Therefore, the aim of the current work was to characterize and specify ¹⁶¹Tb and to develop a protocol for the synthesis and quality control of ¹⁶¹Tb-DOTATOC with a fully automated process conforming to good-manufacturing-practice guidelines, in view of its clinical use. Methods: ¹⁶¹Tb, produced by neutron irradiation of ¹⁶⁰Gd in high-flux reactors followed by radiochemical separation from its target material, was characterized regarding its radionuclidic purity, chemical purity, endotoxin level, and radiochemical purity (RCP) in analogy to what is described in the European Pharmacopoeia for no-carrier-added ¹⁷⁷Lu. In addition, ¹⁶¹Tb was introduced into a fully automated cassette-module synthesis to produce ¹⁶¹Tb-DOTATOC, as used for ¹⁷⁷Lu-DOTATOC. The quality and stability of the produced radiopharmaceutical in terms of identity, RCP, and ethanol and endotoxin content were assessed by means of high-performance liquid chromatography, gas chromatography, and an endotoxin test, respectively. Results: ¹⁶¹Tb produced under the described conditions showed, as the no-carrier-added ¹⁷⁷Lu, a pH of 1-2, radionuclidic purity and RCP of more than 99.9%, and an endotoxin level below the permitted range (175 IU/mL), indicating its appropriate quality for clinical use. In addition, an efficient and robust procedure for the automated production and quality control of ¹⁶¹Tb-DOTATOC with clinically applicable specifications and activity levels, that is, 1.0-7.4 GBq in 20 mL, was developed. The radiopharmaceutical's quality control was also developed using chromatographic methods, which confirmed the product's stability (RCP ≥ 95%) over 24 h. Conclusion: The current study demonstrated that ¹⁶¹Tb has appropriate features for clinical use. The developed synthesis protocol guarantees high yields and safe preparation of injectable ¹⁶¹Tb-DOTATOC. The investigated approach could be translated to other DOTA-derivatized peptides; thus, ¹⁶¹Tb could be successfully applied in clinical practice for radionuclide therapy.

项与镥[177Lu]依多曲肽相关的新闻（医药）

2025-01-29

·药明康德

多肽偶联药物达到3期临床主要终点，计划递交新药申请

▎药明康德内容团队编辑 ITM Isotope Technologies公司日前宣布，其专有的靶向放射性疗法ITM-11，在治疗无法手术切除的进展性1级或2级胃肠胰神经内分泌肿瘤（GEP-NETs）患者的3期临床试验COMPETE中获得积极的顶线结果。数据显示，ITM-11与标准治疗靶向药物相比，达到了延长患者无进展生存期（PFS）这一主要终点。ITM-11耐受性良好，安全性结果令人满意。 COMPETE是一项前瞻性、随机、含活性对照、开放标签的3期临床试验，旨在评估ITM-11与依维莫司（everolimus）这一标准治疗方案相比的疗效和安全性。ITM-11由镥177（一种发射β射线的放射性同位素）和edotreotide组成。Edotreotide是一种生长抑素受体（SSTR）激动剂。 COMPETE试验的次要终点包括客观缓解率、总生存期和生活质量评估，以及对ITM-11在肿瘤与健康组织中吸收剂量的评估。ITM公司计划将这些结果提交至未来的医学会议进行展示，并预计在2025年与FDA讨论潜在新药申请（NDA）的提交。神经内分泌肿瘤是一种罕见的癌症，GEP-NETs起源于神经内分泌系统，由神经细胞和激素分泌细胞组成。GEP-NETs可发生在胃肠道和胰腺的任何部位，包括胃、小肠、结肠、直肠和阑尾。由于许多患者无症状并在晚期出现转移性疾病时才被确诊，治疗选择仍存在巨大未满足的医疗需求。 ITM-11是一种放射性同位素标记的肽偶联药物，能够将β射线靶向递送至SSTR阳性肿瘤细胞中，同时避免对健康器官和组织的损伤。ITM-11通过静脉注射给药，由177镥和edotreotide组成。基于一项回顾性2期研究的积极结果，ITM-11已获得欧盟和美国的孤儿药资格，并在美国获得GEP-NETs适应症的快速通道资格。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). Retrieved January 28, 2025, from https://www.globenewswire.com/news-release/2025/01/28/3016150/0/en/ITM-Announces-Positive-Topline-Results-of-Phase-3-COMPETE-Trial-with-ITM-11-a-Targeted-Radiopharmaceutical-Therapy-in-Patients-with-Grade-1-or-Grade-2-Gastroenteropancreatic-Neuroe.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

放射疗法临床3期临床结果孤儿药临床2期

2025-01-28

·PipelineReview

ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

GARCHING / MUNICH, Germany I January 28, 2025 I ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The data showed that ITM-11 (n.c.a. 177 Lu-edotreotide), a proprietary, synthetic, targeted radiotherapeutic agent, met the primary endpoint of prolonging progression-free survival (PFS) when compared to everolimus, a targeted molecular therapy. ITM-11 was well-tolerated with favorable safety results observed. COMPETE is a prospective, randomized, controlled, open-label Phase 3 trial evaluating the efficacy and safety of ITM-11 compared to everolimus, a standard of care treatment. ITM-11 is comprised of non-carrier-added (n.c.a.) lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a somatostatin receptor (SSTR) agonist. The trial enrolled 309 patients with Grade 1 or Grade 2 inoperable, progressive, somatostatin receptor-positive neuroendocrine tumors of gastroenteric or pancreatic origin (Ki-67 ≤20%). Patients were randomized 2:1 to receive 7.5 GBq of ITM-11 with a nephroprotective amino acid solution every three months for a maximum of four cycles, or everolimus 10 mg daily for up to 30 months, or until disease progression. The COMPETE trial was conducted at multiple sites throughout the world. “With COMPETE, this marks the first time that a targeted radiopharmaceutical therapy has demonstrated improved progression-free survival compared to a targeted molecular therapy, everolimus, in patients with Grade 1 and Grade 2 gastroenteropancreatic neuroendocrine tumors in a Phase 3 clinical trial. The patients included represent a real-life scenario, and the COMPETE study evaluates the important question of which therapy might be used first to provide greater benefit to patients,” said Jaume Capdevila, MD, PhD, study investigator and senior medical oncologist at Vall d’Hebron University Hospital, Barcelona . “As a clinician, I am highly encouraged by these data and look forward to seeing further results.” “We want to thank the patients, families and caregivers, and investigators for their commitment to and trust in this trial. People with GEP-NETs, whose journey from diagnosis to proper treatment can take years, remain in significant need of more robust, data-driven treatment options to maximize outcomes. The successful COMPETE data support ITM-11’s potential and we believe mark an important milestone for patients and for ITM,” said Dr. Andrew Cavey, CEO of ITM . “Our organization now has demonstrated both early and late-stage clinical development capabilities that complement our leadership in global isotope manufacturing.” Secondary endpoints in the COMPETE trial include objective response rate, overall survival, and quality of life assessments. Additionally, dosimetry was used to assess the absorbed ITM-11 dose in tumors compared to that in healthy tissue to enhance monitoring of the patient’s safety and efficacy. These dosimetry data and secondary endpoints, along with subgroup analyses, are currently being evaluated. The company plans to submit the results for presentation at a future medical meeting and anticipates discussing a potential New Drug Application (NDA) submission with the FDA in 2025. In addition to the COMPETE trial, ITM-11 is being evaluated in a Phase 3 trial (COMPOSE) in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. The COMPOSE trial is a prospective randomized, controlled, open-label trial evaluating the efficacy, safety and patient-reported outcomes of ITM-11 as first or second line treatment compared to physician’s choice standard of care chemotherapy. Additional clinical programs with ITM-11 include a Phase 1 pediatric trial in SSTR-positive tumors (KinLET) and a Phase 3 investigator-sponsored trial in lung and thymus neuroendocrine tumors (LEVEL). About GEP-NETS Neuroendocrine tumors (NETs) are a rare form of cancer, with an estimated 8 new cases per 100,000 individuals diagnosed each year in the U.S. and 9 cases per 100,000 in Europe. The incidence of NETs has steadily increased over recent decades, resulting, in part, from improved diagnosis. Gastroenteropancreatic neuroendocrine tumors (GEP-NETS) originate in the neuroendocrine system, and are made up of nerve cells and hormone-producing cells. They can occur anywhere in the GI tract and pancreas, including the stomach, small intestine, colon, rectum, and appendix. There is still a high unmet medical need for treatment options, as many patients are asymptomatic and diagnosed at a late stage with metastatic disease. About ITM-11 (n.c.a. 177 Lu-edotreotide) ITM-11 is a radiolabeled peptide conjugate that delivers beta radiation specifically to SSTR-positive tumor cells, sparing healthy organs and tissue. ITM-11, delivered intravenously, is comprised of non-carrier-added lutetium-177, a therapeutic β-emitting radioisotope, and edotreotide, a synthetic SSTR agonist. ITM-11 was granted orphan drug designation in the EU and the US, and fast track designation in the US for the treatment of GEP-NETs, based on positive results from a retrospective Phase 2 study 1 with 177 Lu-edotreotide. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com References: SOURCE: ITM

临床结果临床3期快速通道孤儿药临床2期

2025-01-28

·FierceBiotech

Longtime manufacturer ITM\'s lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial

German firm ITM Isotope Technologies is ready to take center stage after helping manufacture radiotherapeutics for other biopharmas.\n After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ready to take center stage with drugs of its own. ITM’s lead radiopharmaceutical outperformed the current standard-of-care treatment at prolonging progression-free survival in a phase 3 trial in patients with inoperable neuroendocrine tumors.ITM endeavors to discuss a new drug application for the candidate, called ITM-11, with the FDA in 2025, the company said in a Jan. 28 release. The company also plans to submit the phase 3 results for presentation at a future medical conference, ITM said.The global phase 3 trial enrolled 309 patients with grade 1 or 2 progressive somatostatin receptor (SSTR)-positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs). It compared ITM-11 with targeted molecular therapy everolimus, sold by Novartis as Afinitor for advanced neuroendocrine tumors and other indications.ITM-11 was well tolerated by patients and had favorable safety results, according to the release. ITM did not disclose whether there were adverse events in the trial.The trial’s secondary endpoints of objective response rate, overall survival and quality of life are still being evaluated, ITM said.“People with GEP-NETs, whose journey from diagnosis to proper treatment can take years, remain in significant need of more robust, data-driven treatment options to maximize outcomes,” ITM CEO Andrew Cavey, M.D., said in the release. “Our organization now has demonstrated both early and late-stage clinical development capabilities that complement our leadership in global isotope manufacturing.” That manufacturing leadership includes being the long-term supplier of radioisotope lutetium-177 to Novartis for the creation of metastatic pancreatic cancer drug Pluvicto. Pluvicto is now the most successful radioligand therapy, with sales of $1.04 billion in the first three quarters of 2024.Lutetium-177 is also used in ITM-11, which is delivered intravenously, ITM said.ITM is also testing ITM-11 in multiple other trials, including another phase 3 trial with a different subset of patients with GEP-NETs, those with well-differentiated, aggressive grade 2 or 3 SSTR-positive tumors. A third phase 3 trial is running in patients with lung and thymus neuroendocrine tumors, according to the release, as well as a phase 1 pediatric trial in SSTR-positive tumors.ITM is not putting all of its hopes into one radioactive basket. In addition to ITM-11, the firm has 12 other drug candidates in its pipeline that range in development from preclinical to phase 3.

$Longtime manufacturer ITM\'s lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial$

临床3期临床结果

100 项与镥[177Lu]依多曲肽相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
SSTR阳性胃肠胰神经内分泌肿瘤	临床3期	中国	ITM Solucin GmbH	2025-02-11
SSTR阳性胃肠胰神经内分泌肿瘤	临床3期	中国	远大医药（中国）有限公司	2025-02-11
肺神经内分泌肿瘤	临床3期	法国	Itm Isotope Technologies Munich SE	2023-10-27
肺神经内分泌肿瘤	临床3期	意大利	Itm Isotope Technologies Munich SE	2023-10-27
肺神经内分泌肿瘤	临床3期	西班牙	Itm Isotope Technologies Munich SE	2023-10-27
生长抑素受体阳性神经内分泌肿瘤	临床3期	法国	Itm Isotope Technologies Munich SE	2023-10-27
生长抑素受体阳性神经内分泌肿瘤	临床3期	意大利	Itm Isotope Technologies Munich SE	2023-10-27
生长抑素受体阳性神经内分泌肿瘤	临床3期	西班牙	Itm Isotope Technologies Munich SE	2023-10-27
胸腺肿瘤	临床3期	法国	Itm Isotope Technologies Munich SE	2023-10-27
胸腺肿瘤	临床3期	意大利	Itm Isotope Technologies Munich SE	2023-10-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03049189 (COMPETE, Company_Website) 人工标引	临床3期	胃肠胰神经内分泌肿瘤	309	ITM-11	築鬱糧構淵願範鹹鑰鑰(衊壓餘觸齋構製蓋鹹構) = ITM-11 demonstrating clinically relevant and statistically significant benefit in PFS compared to everolimus 淵鬱顧醖憲蓋衊獵糧艱 (簾築齋鑰觸網繭窪鬱壓 ) 达到	积极	2025-01-28
				Everolimus
NCT04194125 (ESMO 12023 \| ESMO 22023) 人工标引	临床2期	神经内分泌肿瘤	21	177Lu DOTATOC+ CAPTEM	鹹網築獵願鬱糧獵獵簾(廠網繭蓋餘構膚醖積築) = 膚築窪簾積遞蓋顧窪構製構鹽壓鏇淵憲簾獵膚 (鏇鏇鹽廠願艱衊簾遞廠, 16.0 ~ NR) 更多	积极	2023-10-22
				177Lu DOTATOC+ CAPTEM (panNET)	鹹網築獵願鬱糧獵獵簾(廠網繭蓋餘構膚醖積築) = 衊糧構廠襯鏇糧糧憲鑰製構鹽壓鏇淵憲簾獵膚 (鏇鏇鹽廠願艱衊簾遞廠, 14.0 ~ NR)
SNMMI2023	N/A	胃肠胰神经内分泌肿瘤	-	4 cycles of PRRT	餘鹽齋構膚範壓築範餘(築餘鏇淵淵繭夢獵淵築) = 27 of these 36 patients (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) experienced PD in iStaging 廠廠鬱鏇遞獵構繭齋遞 (簾窪繭繭繭廠構鬱衊膚 ) 更多	-	2023-08-28
SNMMI2022	N/A	胃肠胰神经内分泌肿瘤	-	[177Lu]DOTATOC (GEP-NET patients)	壓鹽鑰餘夢顧選壓觸淵(壓網觸簾獵選夢鑰鹽鏇) = 鏇壓積願艱選餘鬱鏇壓憲顧窪醖膚齋壓鑰製夢 (積鹹憲積齋鏇淵積齋鏇 ) 更多	-	2022-08-08
SNMMI2019	N/A	-	-	Lu-177 DOTA-LM3	鹹窪構鑰糧範齋構餘鏇(顧觸築簾鬱夢範鬱觸壓) = 構鬱壓鑰糧範構網鹽憲鑰窪築膚窪顧艱廠構鬱 (顧襯鹽選遞獵鹽選淵構 ) 更多	-	2019-05-21
				Lu-177 DOTATOC	鹹窪構鑰糧範齋構餘鏇(顧觸築簾鬱夢範鬱觸壓) = 簾膚窪蓋窪淵顧窪獵鹽鑰窪築膚窪顧艱廠構鬱 (顧襯鹽選遞獵鹽選淵構 ) 更多
NCT03049189 (COMPETE, ESMO2018)	临床3期	胃肠胰神经内分泌肿瘤	300	Everolimus	繭觸醖夢蓋觸網窪鏇網(獵獵蓋積壓顧築範廠鏇) = 餘製願構構衊夢觸獵觸鹽觸醖蓋鹹鑰構膚糧齋 (艱餘顧觸鏇糧憲繭製構 )	-	2018-10-21